LifeSci Capital analyst Rahul Rakhit maintained a Buy rating on Akili (AKLI – Research Report) today and set a price target of $5.00. The company’s shares closed today at $1.44.
According to TipRanks, Rakhit is an analyst with an average return of -52.9% and a 7.50% success rate. Rakhit covers the Healthcare sector, focusing on stocks such as DarioHealth, Akili, and Better Therapeutics, Inc..
Akili has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $37.58 and a one-year low of $0.86. Currently, Akili has an average volume of 317.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Social Capital Suvretta Holdings Corp I is a blank check company.
